Humoral immune response to recombinant adenovirus and adeno-associated virus after in utero administration of viral vectors in mice

Pediatric Research

Volumn 52, Issue 1, 2002, Pages 95-104

  Jerebtsova, Marina ^a   Batshaw, Mark L ^a,b   Ye, Xuehai ^a,b  

^a CHILDREN S RESEARCH INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; HUMAN GROWTH HORMONE; NEUTRALIZING ANTIBODY;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; GENE EXPRESSION; HUMORAL IMMUNITY; INTRAAMNIOTIC DRUG ADMINISTRATION; INTRAHEPATIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 0036081135     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-200207000-00018     Document Type: Article

References (48)

1. Intrauterine gene transfer: Gestational stage-specific gene delivery in mice
2. In utero gene transfer into the pulmonary epithelium
3. Ultrasound-guided gene transfer to hepatocytes in utero
4. Adenovirus-mediated gene transfer to the respiratory tract of fetal sheep in utero
5. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors
6. In utero delivery of adeno-associated viral vectors: Intraperitonial gene transfer produces long-term expression
7. Humoral immunity to adeno-associated virus type 2 vector following administration to murine and nonhuman primate muscle
8. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
9. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
10. The window of opportunity for fetal gene therapy
11. Urea cycle enzyme
12. In utero hematopoietic stem cell transplantation and gene therapy
13. In utero stem cell transplantation
14. Pulmonary inflammation associated with repeated, prenatal exposure to an E1, E3-deleted adenoviral vector in sheep
15. Persistent postnatal transgene expression in both muscle and liver after fetal injection of recombinant adenovirus
16. Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia
17. Prolonged metabolic correction in adult ornitine transcarbamilase-deficient mice with adenoviral vectors
18. Adenoviral vectors
19. Gene therapy vectors based on adeno-associated virus type I
20. Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration
21. Actively acquired tolerance to foreign cells
22. Induction of tolerance in nondefective mice after in utero transplantation of major histocompatibility complex-mismatched fetal hematopoietic stem cells
23. Development of adults bone marrow stem cells in H-2 compatible and incompatible mouse fetuses
24. Prevention of genetic anemias in mice by microinjection of normal hematopoietic stem cells into the fetal placenta
25. Induction of immunity to antigens expressed by recombinant adenoassociated virus depends on the route of administration
26. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors
27. Characterization of T cell precursor activity in the murine fetal thymus: Evidence for an input of T cell precursors between days 12 and 14 gestation
28. One synchronous wave of B cell development in mouse fetal liver changes at day 16 of gestation from dependence to independence of a stromal cell environment
29. Localization dose and time of antigens determine immune reactivity
30. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice
31. Long-term humoral and cellular immunity induced by a signal immunization with replication-defective adenovirus recombinant vector
32. Adeno-virus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
33. Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression
34. Adenovirus-transgenic mice: Partial embrionic lethality and lack of immunological tolerance to adenoviral vectors
35. Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells
36. Danger signals: SOS to the immune system
37. Induction of stable prenatal tolerance to b-galactosidase by in utero gene transfer into preimmune sheep fetuses
38. Antivector and antitransgene host responses in gene therapy
39. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line
40. Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies
41. Insertion of an RGD motif into the H1 loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector
42. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice
43. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
44. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
45. Cyclophosphamide diminishes inflammation and prolong transgene expression following delivery of adenoviral vectors to mouse liver and lung
46. Risk and preventation of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9
47. Transient depletion of CD4 lymphocyte improves efficacy of repeted administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mice